Apogee Therapeutics, Inc. APGE R2KR3KPHARMA
Company Overview
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +261.54% |
| 6 Months: | +90.45% |
| 3 Months: | +48.59% |
| 1 Month: | +0.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)78.61 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APGE Apogee Therapeutics, Inc. R2KR3KPHARMA | 135.07 | -31.19 | $8.33B | 0.00% | -31.41% | -28.47% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 63.10M | 73.17M | 71.28M | 78.06M | 82.77M | - |
| Operating Income | -1.82M | -10.51M | -12.66M | -18.89M | -24.30M | -38.18M | -44.12M | - | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M | -96.00M |
| EBITDA | - | - | - | - | - | - | - | - | -62.89M | -72.77M | -70.87M | -77.65M | -82.36M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -55.26M | -66.02M | -64.96M | -69.33M | -74.03M | - |
| Tax Provision | - | - | - | - | - | - | - | - | 83.00K | 72.00K | 61.00K | 62.00K | 79.00K | - |
| Net Income | -1.82M | -19.66M | -12.53M | -18.89M | -20.84M | -32.09M | -33.82M | - | -55.34M | -66.10M | -65.02M | -69.39M | -74.11M | -85.85M |
| Diluted EPS | -1.45 | -9.46 | -2.51 | -3.78 | -0.51 | -0.64 | -0.60 | -0.86 | -0.93 | -1.11 | -1.08 | - | -1.06 | -1.14 |
| R&D Expense | 1.45M | 9.88M | 8.46M | 13.95M | 17.07M | 28.72M | 33.21M | 45.71M | 46.39M | 55.70M | 54.18M | - | 60.82M | 67.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 30.73M | 93.00M | 216.87M | 285.60M |
| Operating Income | -30.73M | -93.00M | -216.87M | -285.60M |
| EBITDA | -30.64M | -93.00M | -216.68M | -284.18M |
| Interest Expense | 9.15M | 0 | - | - |
| Pretax Income | -39.78M | -83.98M | -182.13M | -255.56M |
| Tax Provision | - | 0 | 18.00K | 278.00K |
| Net Income | -39.78M | -83.98M | -182.15M | -255.84M |
| Diluted EPS | -1.46 | -3.36 | -3.30 | -3.74 |
| R&D Expense | 27.79M | 68.42M | 167.87M | 214.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 152.06M | 401.40M | 753.95M | 937.13M |
| Current Assets | 152.06M | 398.41M | 529.71M | 741.36M |
| Cash & Equivalents | 151.89M | 118.32M | 141.79M | 131.55M |
| Inventory | - | - | - | - |
| Receivables | - | 1.21M | 4.70M | 5.96M |
| Total Liabilities | 9.98M | 21.49M | 37.16M | 33.25M |
| Current Liabilities | 9.98M | 20.56M | 28.56M | 27.91M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 2.03M | 11.83M | 8.85M |
| Total Equity | 0 | 379.91M | 716.79M | 903.88M |
| Shares Outstanding | 48.02M | 48.52M | 59.48M | 68.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -16.43M | -74.76M | -171.17M | -227.45M |
| Investing Cash Flow | 0 | -273.91M | -300.46M | -179.57M |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Capital Expenditure | - | -167.00K | -1.15M | -5.15M |
| Free Cash Flow | -16.43M | -74.93M | -172.33M | -232.60M |
| Net Change in Cash | 151.89M | -33.28M | 23.47M | -10.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | - | -22.1% | -25.4% | -28.3% |
| ROCE % | -21.6% | -24.4% | -29.9% | -31.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Venrock Adviser, LLC | 13.65% | 8.49M | $1.15B |
| 2 | Blackrock Inc. | 8.85% | 5.51M | $743.28M |
| 3 | HBK Investments L P | 4.58% | 2.85M | $384.66M |
| 4 | Vanguard Capital Management LLC | 4.14% | 2.57M | $347.16M |
| 5 | FMR, LLC | 4.01% | 2.49M | $336.50M |
| 6 | State Street Corporation | 3.69% | 2.30M | $310.13M |
| 7 | Driehaus Capital Management, LLC | 2.80% | 1.74M | $234.86M |
| 8 | Goldman Sachs Group Inc | 2.72% | 1.69M | $228.55M |
| 9 | Balyasny Asset Management LP | 2.68% | 1.67M | $224.74M |
| 10 | Glazer Capital LLC | 2.64% | 1.64M | $221.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APGE
APGE Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1tQlJublNtVDlkUmVjODEwNHZNM2l4TEpBR1pCckc1VGUzLThPdXZlN3JrZ3lNTFVxR3FFZ2dPTVFjM2hXY3lsMjFqUjhoWkJ4YjBBQnNFOG1WUllmX1Zn?oc=5" target="_blank">APGE Stock Price, Quote & Chart</a>&nbs…
Apogee Therapeutics Completes Merger and Plans Nasdaq Delisting - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOWnNiVVNKaG1kQWtlMWZON2E1dFNuWXNlaWNnSG1pOG1UanBiSFp2Uk9FeVNaU0ZOUDdtR19jVlV5dzNxbmdab0xYOVB0THg1VjluQ0gyVHpTMGFjam11Q2hWVkZHVk11R280b3F6bEN2czdsTGFrQV92T04yR0tJRkNIMlFSYWlESGZ4bE…
Apogee (NASDAQ: APGE) director swaps options for cash in AbbVie deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbDIxOGVZY192ZFpDNkdOUjZobUVTVTIwblhidW85RXJjdjZ1VXNRdkNObDQ5ejZuRWlVVHBONmFCV1ZYRlpwZ0IyZGdkSDZldkQtMThLVDFRcjlRbG9vUUdTZ3gwQ1ItTHJqZm1rdGtuM0wtZjk0THJBUDdlS1ZDWUNYT1dJS2ZHa1BHZW…
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQamhkeXFTdDJPM3lQOUJyd0FVOXhERXRobGc1VUFQTUpEVG9Vc3M0SW9xUXpTUkhLM0ExN05kZndYOVpuek1qMW9ZUWxhQi14SWpWMzhaOWUwS1FXU1Mta0VWdGsyd3JlZ0xvblZWcnZ0UWUzQjNBd0FuVnk4bnlRM1hjTF82RllUR0RnNk…
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPUVNIREVTbmg0SXJ2NlZRbWdOUXVtNU9jMDA1VFlkSnJmb3hobElhanQxOU9nUnJvejYtSWhKM3g1RWJyaXU0T19Yd2tPU3ZTMzFMQURiaXgzSE9IbVY3U291a2RTSkduZWo2WTZOUjc5cUdubXpQOGNpcXNZb2JmNzhNMkFaM18yd19WVm…
APGE - Apogee Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1nR3NoSVpObklCcHNpUE0tcVd0RjBCTzdYRDJDMEdzN05YdWNlTjFHYXJZY3FTdjlHVnYyeDdwdDc5Tzd1RkE?oc=5" target="_blank">APGE - Apogee Therapeutics Inc Stock Price and Quote</a> <fon…
APGE — Frequently Asked Questions
What is the current share price of Apogee Therapeutics, Inc. (APGE)?
As of 2026-09-07 16:24 PDT, Apogee Therapeutics, Inc. (APGE) trades at $135.07 on NasdaqGM. Its 52-week range is $36.02 to $135.08.
What is the market capitalisation of APGE?
Apogee Therapeutics, Inc. (APGE) has a market capitalisation of $8.33B on NasdaqGM.
What is the P/E ratio of APGE?
APGE trades at a trailing price-to-earnings (P/E) ratio of -31.19. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.99.
What is the return on equity (ROE) of APGE?
APGE has a return on equity (ROE) of -28.47%. Its return on capital employed (ROCE) is -31.41%.
Is APGE a good stock to buy?
This page provides a data-driven analysis of Apogee Therapeutics, Inc. (APGE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.